Hepion Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Gary S. Stetz Ii, a Director of Hepion Pharmaceuticals, Inc., purchased 1,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
OQB
Gary S. Stetz, Interim CEO and a Director of Hepion Pharmaceuticals, Inc., purchased 4,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
OQB
Michael J. Purcell, a Director of Hepion Pharmaceuticals, Inc., purchased 4,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
OQB
Sireesh Appajosyula, Chief Operating Officer and a Director of Hepion Pharmaceuticals, Inc., purchased 4,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
OQB
Vincent S Lopriore, Executive Chairman and a Director of Hepion Pharmaceuticals, Inc., purchased 20,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
OQB
Director Michael J. Purcell acquired 1,250,000 shares of Hepion Pharmaceuticals, Inc. common stock at $0.04 per share.
OQB
Vincent S. LoPriore, Executive Chairman and Director of Hepion Pharmaceuticals, acquired a significant number of common shares through affiliated entities.
OQB
Hepion Pharmaceuticals Director Appajosyula Sireesh reports a significant transaction involving common stock.
OQB
Gary S. Stetz, Interim CEO and Director of Hepion Pharmaceuticals, acquired 1,250,000 shares of common stock.
OQB
Hepion Pharmaceuticals received a notice from Nasdaq indicating non-compliance with listing rules due to a stockholders' deficit reported in their recent quarterly filing.
OQB
Hepion Pharmaceuticals received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for continued listing.
OQB
Hepion Pharmaceuticals reports the departure of its interim CEO and CFO, John Cavan, and the appointment of John Brancaccio as the interim replacement, effective August 6, 2024.
OQB
Hepion Pharmaceuticals plans to merge with Pharma Two B, a late-clinical stage Israeli company, to advance the development of P2B001 for Parkinson's Disease and list on Nasdaq, accompanied by a $11.5 million private placement.
OQB
Director Michael J. Purcell of Hepion Pharmaceuticals acquired 50,000 restricted stock units (RSUs) on March 6, 2024, which convert to common stock upon vesting.